000			05725nam a22003855i 4500
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
988			_aSpringer_Medicine_2018
999			_c343862 _d343862 _x1
001			343862
003			ES-MaUEC
005			20230102120149.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			180906s2018 si | s |||| 0|eng d
020			_a9789811084140
024	7		_a10.1007/978-981-10-8414-0 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
050		4	_aR853.O87 _b2018 EB
100	1		_aKamudoni, Paul. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut
245	1	0	_aLiving with Chronic Disease: Measuring Important Patient-Reported Outcomes _cby Paul Kamudoni, Nutjaree Johns, Sam Salek.
264		1	_aSingapore _bSpringer Singapore : _bImprint: Adis _c2018.
300			_a1 recurso en línea (XII, 165 páginas) _b14 ilustraciones, 9 ilustraciones a color
490			_aMedicine (Springer-11650)
505	0		_a1. Overview -- 2. Approaches to the Development and Use of PROs: A Unified Framework -- 3. An Illustration of the New PRO Measure Development Roadmap Using an Example from Skin Disease -- 4. Determination of Fitness for Purpose: Content Verification by Patients and Experts -- 5. Conventional Methods Meeting Modern Techniques: Factor Analysis Versus Rasch Analysis -- 6. Assessing the Performance of PROs Against Expectation: Psychometric Calibration -- 7. Integrating Patient Reported Outcomes in Clinical Trials, Routine Clinical Practice and Medicines Development Programmes.
520			_aThis book serves as a roadmap for the development and application of patient-reported outcome (PRO) measures, supporting beginners through to experts, as a practical guide. To elucidate on key concepts in the book, examples from clinical research in hyperhidrosis and health-related quality of life and medicines clinical development context, are used. Health-related quality of life represents one of the most commonly measured PROs in both routine clinical practice and research. The book demonstrates the importance of PROs to patients with chronic disease and how such outcomes can assist clinicians in managing patients and monitoring their response to treatment in terms of both symptoms and impacts. This book will benefit readers as a single-source practical guide on the development of modern PRO measures and may also serve as a blueprint for the conceptualization and planning of evidence generation related to PROs in various settings. Ideas and suggestions on how to navigate recent developments shaping the field of PRO measurement are also offered. Dr Paul Kamudoni (PhD MSc.) is a Scientific Associate Director in the Global Evidence and Value Development - R&D department at Merck KgaA in Darmstadt (Germany) where he leads the Centre of Excellence for Patient Reported Outcomes. Dr Kamudoni trained as a Pharmacoeconomist and a Clinical Outcome Measurement Scientist at Cardiff University. In his day to day work, he is involved in the development and validation of PRO measures, and the design and integration of PRO endpoints in clinical trials and other types of studies. He maintains an active research interest in methodological issues in the integration of electronic health records with prospective PRO assessments, and the application of item response theory in PRO measurement among others. Dr Nutjaree Pratheepawanit Johns (PhD PharmD) is an Associate Professor at the Faculty of Pharmaceutical Sciences, and melatonin research group, Khon Kaen University, Thailand. She has held a number of academic positions both in Thailand and abroad, including a fellowship at the Western Institutional Review Board (WIRB) (Olympia, WA, USA). Dr Johns has an expertise in cancer care and quality of life (QoL) research and collaborates with several cancer centres in Northeastern Thailand. She has developed and tested a number of PRO measures including cross-cultural adaptation into the Thai language. Dr Johns is also a principal investigator in many clinical trials investigating the effects of disease or interventions on QoL of cancer patients. She has been a recipient of several prestigious awards including Scholarship for Developing Country, International Society for Quality of Life Research and the Doyle Prize: Postgraduate section, Palliative Medicine Journal. Professor Sam Salek (PhD RPh FFPM FRPS MCMS FESCP) is Professor of Pharmacoepidemiology at the University of Hertfordshire, Hatfield, visiting Professor at the Estate of Hessen, Germany, and Director of the Institute for Medicines Development, Cardiff, UK. Professor Salek's research focuses mainly on four areas: development and application of PRO measures; drug safety evaluation and pharmacovigilance; pharmacoeconomics and economic evaluation of healthcare; and pharmaceutical regulation & medicines development in the mature and emerging markets. He has published 22 books and 600+ journal articles and abstracts. Professor Salek is a member of five Editorial Boards and an active member of several societies.
650		7	_2embne _9168783 _aMedicina _xInvestigación
700	1		_aJohns, Nutjaree. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut
700	1		_aSalek, Sam. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _936810
776	0	8	_iPrinted edition: _z9789811084133
776	0	8	_iPrinted edition: _z9789811084157
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-10-8414-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _a_alco _a_vill _b02/2019 _cm _dz _feng _ggw _h0